Skip to content
Tokyo Brief東 京 ブ リ ー フJapan's day, wrapped and delivered by morning.
Company
Companies

GNI Group

ジーエヌアイグループ

2160 · TSE · Pharmaceutical · 4 articles

Financials Consolidated

Revenue¥26.8bn+13.7% year on yearConsolidated · FY12/25

Operating profit−¥3.47bnConsolidated · FY12/25

Net profit−¥4.24bnConsolidated · FY12/25

Performance over time

Revenue
¥12.7bnFY12/21
¥17.4bnFY12/22
¥26.0bnFY12/23
¥23.6bnFY12/24
¥26.8bnFY12/25
Net profit (attributable)
¥1.07bnFY12/21
¥388mFY12/22
¥8.09bnFY12/23
¥1.10bnFY12/24
−¥4.24bnFY12/25
Op. cash flow
¥552mFY12/21
¥393mFY12/22
¥6.55bnFY12/23
−¥3.16bnFY12/24
−¥2.41bnFY12/25

People & pay

Employees, whole group990 peopleFY12/25

Employees, parent company (non-consolidated)14 peopleFY12/25

Average salary¥8.00mFY12/25

Average salary is for the parent company's own employees (non-consolidated), as Japanese annual reports disclose it.

Five-year history
Five-year history
Fiscal yearRevenueOp. profitNet profit (attributable)EPSTotal assetsTotal equityOp. cash flow
FY12/25¥26.8bn+13.7% year on year−¥3.47bn−¥4,244m−¥80.90¥83.8bn¥51.8bn−¥2,408m
FY12/24¥23.6bn−9.2% year on year¥1.40bn¥1,098m¥21.96¥71.9bn¥39.7bn−¥3,164m
FY12/23¥26.0bn+49.3% year on year—¥8,094m¥169.50¥64.3bn¥36.5bn¥6,549m
FY12/22¥17.4bn+37.3% year on year—¥388m¥8.19¥33.9bn—¥393m
FY12/21¥12.7bn—¥1,066m¥22.72¥30.3bn—¥552m

Per-share figures are as each report states them: a share split is restated only for the year before it, and dividends are as paid.

Figures from annual report S100XV4B · IFRS. Each figure's years come from one report's five-year summary.

Latest coverage

TSE:2160

Tokyo Brief coverage

  1. GNI Group plans ¥44.776 billion Ayumi buyout, with sellers paid partly in stock

    GNI plans to buy all of Ayumi Pharmaceutical Holdings for ¥44.776 billion and make it a wholly owned unit, arguing the deal adds a steadier Japanese earnings base plus an established sales network in rheumatology, orthopedics and fever-and-pain drugs. Ayumi reported revenue of ¥38.543 billion and operating profit of ¥6.206 billion in the year to March 2026, giving GNI a domestic commercial platform rather than just another pipeline promise. The financing is the real tell. GNI will pay ¥18.005 billion in cash and settle ¥26.771 billion through a contribution in kind, issuing 9,974,291 new shares to the sellers, while also lining up ¥20 billion of borrowing from Mizuho Bank and SBI Shinsei Bank. Management says the deal should close between June 30 and September 30, but existing holders face 17.89% share dilution and BCP is expected to emerge as the largest shareholder.

All articles loaded · 4 shown

5% holders

Latest disclosed holders and exits below 5%.

1 holder · data through

No stored data for this selection.

Exits below 5%

Exits below 5%
HolderStakeChangePurposeFiling
BCP Asia AYM Holding(Cayman)L.P.4.97%−5.64 ppPure investmentPure investment
Original (Japanese)純投資
Filed  — filing S100ZBCD

Cross-holdings

Strategic shareholdings and sales, by fiscal year.

5 fiscal years · data through

Balance-sheet value is the reporting company's own listed holdings (its largest holding subsidiary's where marked), carried at market value; the percentage divides it by consolidated net assets in the same annual report.

Cross-holdings
Fiscal year endHoldings (issuers)Balance-sheet value% of consolidated net assetsIssues cutSale proceedsFiling
31 Dec 2024No listed strategic holdings reported————Filed 
Show 4 more fiscal years (5 total)
Cross-holdings
Fiscal year endHoldings (issuers)Balance-sheet value% of consolidated net assetsIssues cutSale proceedsFiling
31 Dec 2023No listed strategic holdings reported————Filed 
31 Dec 2022No listed strategic holdings reported————Filed 
31 Dec 2021Largest holding subsidiary1¥228m———Filed  — filing S100NYW8
31 Dec 2020No listed strategic holdings reported————Filed 

Fund positioning

Current holdings disclosed by tracked funds.

20 funds · data through

Held by 20 tracked funds; largest weight 13.24%. Holdings as of 31 Jul 2026–20 Nov 2026.

Show 10 more funds (20 total)